Blood Test for Alzheimer’s Cleared by FDA
An FDA-cleared blood test that measures key Alzheimer’s disease biomarkers is a less invasive, more accurate method to diagnose the condition.
An FDA-cleared blood test that measures key Alzheimer’s disease biomarkers is a less invasive, more accurate method to diagnose the condition.
Microglia can transition from protective to harmful with age, producing inflammatory messengers like IL-12, which accelerates Alzheimer’s.
Neurocode USA Inc. published a study showing that its ALZpath pTau217 assay outperforms the Fujirebio assay in detecting Alzheimer's disease.
Researchers have visualized the atomic-level structure of protein clumps linked to Huntington’s disease, paving the way for diagnostic tools.
Read MoreThis episode of Clinical Lab Chat covers the how and why of making precise clinical diagnosis of neurodegenerative diseases.
Read MoreTwo universities are conducting a validation study on a blood test designed to detect early neurodegeneration in Alzheimer’s disease.
Read MoreA new study demonstrates the clinical utility of a skin biopsy diagnostic tool in improving care for those with neurodegenerative diseases.
Read MoreResearchers identified a promising blood biomarker for detecting vascular contributions to cognitive impairment and dementia.
Read MoreBlood-based diagnostics for Alzheimer’s disease and other neurological conditions could be here sooner than you think.
Read MoreResearchers explored how combining CSF analysis and amyloid PET imaging can improve the accuracy and efficiency of Alzheimer’s diagnosis.
Read MoreStudy results were revealed for the VeraBIND Tau assay diagnostic test designed to detect active Alzheimer’s disease pathology.
Read MoreA new capillary blood test offers a simple, mail-in method to detect Alzheimer’s biomarkers, paving the way for accessible global testing.
Read MoreSunbird Bio demonstrated that its blood-based alpha synuclein biomarkers can accurately detect Parkinson’s disease.
Read MoreVeravas and Phanes Biotech are collaborating to create a blood test using VeraBIND technology to detect Alzheimer’s tau pathology early.
Read MoreRoche announced the Elecsys Amyloid Plasma Panel shows promising results in accurately ruling out amyloid pathology in Alzheimer’s disease.
Read MoreResearchers have found a significant link between olfactory loss in 139 medical conditions, highlighting the role of smell plays.
Read MoreLucent Diagnostics launched a blood test using five Alzheimer’s-related biomarkers to improve detection accuracy and reduce invasive testing.
Read MoreBrainScope completed the proof-of-concept phase for a novel EEG-based biomarker capable of predicting the onset of Alzheimer’s disease.
Read More